ANOMALI
29.7.2021 17:04:07 CEST | Business Wire | Press release
Anomali , the leader in intelligence-driven cybersecurity solutions, today announced availability of its latest survey conducted by The Harris Poll. The study, which gathered responses from more than 1,000 adults aged 18 and over in the United Kingdom, reveals that more than three-quarters of British adults have cybersecurity fears around the use of COVID-19 digital vaccination cards. Additional findings showed which entities respondents believe are responsible for protecting them against cyberattacks and who they believe the most likely culprits will be.
A majority of respondents predict that a disruptive cyberattack will follow digital vaccine card adoption, findings also reveal confidence levels when it comes to how prepared the nation is to mount a defense. Among key findings:
- 76% have cybersecurity concerns related to COVID-19 digital vaccination cards. Identity theft topped the list at 51%, with fake vaccine cards that could be used to hack smartphones (44%) and data breaches (45%) close behind.
- 89% have smartphones capable of supporting COVID-19 digital vaccination cards. In contrast, a survey conducted a little over a year ago by Anomali and Censuswide showed that half of respondents knew someone that did not possess smartphones necessary to use healthcare technologies such as contract tracing apps.
- 54% say they are “very likely” to use COVID-19 digital vaccination cards if they become a requirement for certain activities, such as traveling, attending sports venues, school attendance, entering a store or government building, etc. However, doubt remains, as 26% said they are “somewhat” likely. A full 21% rejected the idea of using digital vaccine cards, stating they are not likely to use them at all.
- 64% expect that COVID-19 digital vaccination cards will lead to a cyberattack causing “moderate to major” disruption to business, government, and consumers. 27% said that disruption would only be “slight” while 9% do not expect any related disruptions.
- When asked to identify what type of adversary is most likely to carry out a cyberattack related to COVID-19 digital vaccination cards, organized cybercriminal gangs were most frequently cited (42%).
- 64% “somewhat to strongly” agree that government and private business is prepared to defend consumers against a related cyberattack. 74% said the government was most responsible for providing defense.
- Although COVID-19 passport standards haven’t been established, when asked to pick from a list of organizations that will most likely be responsible for creating and managing standards, the government was most frequently cited (55%), the World Health Organization (WHO) came in second (44%).
“Over the course of the pandemic, our intelligence analysts detected thousands of cyberattacks that were taking advantage of people’s desire to consume information online about how COVID-19 was impacting their lives and world. We’ve detected adversaries doing everything from using fake contact tracing apps to hijack smart phones and steal credentials to launching mass phishing campaigns to infect networks with things like ransomware,” said Hugh Njemanze, President, Anomali. “The easing of restrictions, rise in cyberattacks, and consumers’ willingness to use their smartphones to break free from restrictive lockdowns are at a nexus. Organizations responsible for keeping consumers and businesses safe online need to know who the adversaries are, where the attacks are coming from, and how to detect them before they develop into catastrophes.”
- Download the ebook: COVID-19: The Global Health Pandemic and Cybersecurity Challenges
- Read the blog: The COVID-19 Pandemic Changed Everything, Can You Detect the New Normal?
- View the infographic: COVID-19 DIGITAL VACCINE EFFORTS MAY STALL AMID FEARS
Methodology
This survey was conducted online by The Harris Poll on behalf of Anomali from June 30 – July 7, 2021 among 1,007 U.K. adults all ages 18 and older. Raw data were weighted by the following demographic variables where necessary to reflect the general adult population as follows: age, gender, education, region, race, HH size, and marital status. Propensity score weighting was also used to adjust for respondents’ propensity to be online. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About The Harris Poll
The Harris Poll is one of the longest-running surveys in the U.S., tracking public opinion, motivations and social sentiment since 1963. It is now part of Harris Insights & Analytics, a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. We work with clients in three primary areas; building twenty-first century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Our mission is to provide insights and advisory to help leaders make the best decisions possible.
About Anomali
Anomali is the leader in global intelligence-driven cybersecurity. Our customers rely on us to see and detect threats, stop breaches, stop attackers, elevate resiliency, and improve the productivity of their security operations. Our solutions serve customers around the world in every major industry vertical, including many of the Global 1000. We are a SaaS company that offers native cloud, multi-cloud, on-premises, and hybrid technologies. As an early threat intelligence innovator, Anomali was founded in 2013 and is backed by leading venture firms including Google Ventures, IVP, General Catalyst, and several others. Learn more at www.anomali.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005800/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
